

Outcome of Review of the Company's Continuous Disclosure Procedures Relating to the Release of Material Information Generated Through Collaborative Research

Bio-Gene Technology Limited (ASX: BGT, Bio-Gene or the Company), an Australian company developing the next generation of novel insecticides derived from nature, provides this update to the market in relation to its recent review of the Company's policies and procedures relevant to its continuous disclosure obligations. This review related to BGT's compliance with Listing Rule 3.1 and its reliance on the exceptions in Listing Rule 3.1A in the context of the release of material scientific information (**Information**) generated through external collaborative scientific research, pursuant to Listing Rule 18.8.

The Company announced on 22 October 2025 that it would be undertaking this review at the direction of the ASX following the sequence of events leading up to the Company's announcement on 23 September 2025 titled '*Positive Flavocide Efficacy Results Presented*'.

The Company has now completed its review and has taken the following steps in response to the ASX direction:

1. revised its Communication and Disclosure Policy (**Policy**) to include a specific checklist and escalation protocol for each of the steps leading up to the first public disclosure of scientific data generated by external research institutions on BGT's products. This includes pre-agreeing procedures to govern disclosures by BGT, and coordinating interactions with external researchers and academic collaborators before new scientific information is first disclosed publicly at conferences and in scientific publications. These changes ensure that the first public disclosure of any such market-sensitive information will be via the ASX Market Announcements Platform (**MAP**).
2. implemented a more comprehensive pre-clearance process for the internal dissemination and review of any externally created scientific presentations and other publications that may contain potentially market-sensitive information. This includes the assessment of disclosure obligations under Listing Rule 3.1 and the applicability of the exceptions under Listing Rule 3.1A. In addition, the agenda for board meetings has been modified to enhance earlier review in preparation for the release of any such scientific information and publications; and
3. key personnel have recently completed, or are in the process of completing, the ASX Listing Rules Compliance Course, and management and the directors have discussed enhancements to ensure future compliance by BGT with Listing Rules 3.1 and 3.1A, with emphasis on management of the process leading up to the disclosure of externally created scientific information.

Approved for release on ASX by Bio-Gene Board of Directors.

- ENDS -

For further information, please contact:

Bio-Gene Technology Limited:
E: bgt.info@bio-gene.com.au

Matthew Wright
NWR Communications
E: matt@nwrcommunications.com.au
M: 0451 896 420

About Bio-Gene Technology Limited

Bio-Gene is an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance. Its unique products are based on a naturally occurring class of compounds proven to overcome resistance, and to control pests with minimal impact on human health and the environment.

Bio-Gene's products have multiple applications across crop protection, grain storage, public health and consumer uses. They provide new options derived from nature to meet market demand for effective and safe pest management solutions.

www.bio-gene.com.au

Flavocide® and Qcide® are registered trademarks of Bio-Gene Technology Limited.
